학술논문
Ibrutinib significantly inhibited Bruton’s tyrosine kinase (BTK) phosphorylation,in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model
Document Type
article
Author
Chu, Yaya; Lee, Sanghoon; Shah, Tishi; Yin, Changhong; Barth, Matthew; Miles, Rodney R; Ayello, Janet; Morris, Erin; Harrison, Lauren; Van de Ven, Carmella; Galardy, Paul; Goldman, Stanton C; Lim, Megan S; Hermiston, Michelle; McAllister-Lucas, Linda M; Giulino-Roth, Lisa; Perkins, Sherrie L; Cairo, Mitchell S
Source
OncoImmunology. 8(1)
Subject
Language
Abstract
Pediatric and adult patients with recurrent/refractory Burkitt lymphoma (BL) continue to have poor outcomes, emphasizing the need for newer therapeutic agents. Bruton's tyrosine kinase (BTK) is activated following B-cell receptor stimulation and in part regulates normal B-cell development. Ibrutinib, a selective and irreversible BTK inhibitor, has been efficacious in chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenström's macroglobulinemia, and marginal zone lymphoma. In this study, we investigated the efficacy of ibrutinib alone and in selective adjuvant combinations against BL in-vitro and in a human BL xenografted immune-deficient NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mouse model. Our data demonstrated that phospho-BTK level was significantly reduced in BL cells treated with ibrutinib (p